Company Overview and News

 
MF Wrap: Why mutual funds pared stake in NBFCs, HFCs in September?

2018-10-13 moneycontrol
Mutual funds pared stake in most non-banking and housing finance companies or NBFCs in September as defaults in repayment by group companies of Infrastructure Leasing & Financial Services (IL&FS) and subsequent ratings downgrades led to fears of a contagion in the sector.
511218 535789 IBULHSGFIN DHFL RELCAPITAL 511072 SRRQY IDKQY SRTRANSFIN 500111

 
Shriram Transport NCD issue opens on Monday

2018-10-12 thehindubusinessline
Shares of Shriram Transport Finance Company will remain in focus on Monday on fund-raising plans. The NBFC plans to raise ₹300 crore through secured redeemable non-convertible debentures with an option to retain oversubscription of up to ₹1,050 crore, aggregating up to ₹1,350 crore. The issue will close on October 29. It plans to use the funds for onward lending and for repayment/prepayment of interest and principal of existing borrowings.
511218 SRRQY SRTRANSFIN

5
Markets stage relief rally; banking, auto stocks lead

2018-10-10 freepressjournal.in
Mumbai: Benchmark indices staged a strong comeback Wednesday after the recent rout as investors accumulated battered financials, auto and metal stocks amid rupee recovery from record lows. The BSE Sensex, after a gap up opening of 34,493.21, rallied to hit a high of 34,858.35 before ending 461.42 points, or 1.35 per cent, higher at 34,760.89. The broader Nifty too reclaimed the key 10,400 mark. It touched a high of 10,482.
BAJAJ-AUTO 500820 BNPQY 532978 532977 SRTRANSFIN BHRQY ASIANPAINT 533278 532215 511218 500470 532187 AXISBANK SRRQY HDFCBANK HEROMOTOCO 500570 BHARTIARTL TATAMOTORS CLNDY YESBANK INDIGO AXB INDUSINDBK IBN 532648 YYBKY BNPQF 539448 AXBKY 532454 500182 BNPZY AXBA ICICIBANK BAJAJFINSV TTST TATASTEEL TATLY HDB 532174 500180 HRTQY COALINDIA TTM

3
IL&FS defaults could derail robust growth of NBFCs as stricter regulations soon to be in place

2018-10-08 financialexpress
The fastest pace of growth since 2013 at India’s non-bank financiers is about to come to a grinding halt. A spate of money market defaults by Infrastructure Leasing & Financial Services Ltd. has put the spotlight on non-bank finance companies. With banks struggling with bad loans and low capital buffers, non-bank lenders had rushed to tap demand for long-term financing to build roads, power plants and homes.
DSLV EDELWEISS VIIX DGLD CSSLF VIIZ IIFL 532922 532636 SRTRANSFIN CS 511218 CSGKF UGLD MAGMA SRRQY ZIV USLV 524000 TVIX XIV

 
Shriram Transport rises 4% as UBS maintains buy with potential upside of 44%

2018-10-04 moneycontrol
Share price of Shriram Transport Finance Corporation added 4 percent intraday Thursday as research house UBS has maintained buy rating on stock with potential upside of 44 percent.
511218 SRRQY SRTRANSFIN

 
D-Street Buzz: Nifty Energy underperforms as RIL sheds 4%; Maruti hits new 52-week low, metals shine

2018-10-04 moneycontrol
With rupee hitting fresh record low at 73.60 per dollar which also scaled 11-month peak on yen as US yields surge, the impact is severe on the Indian stock market. The Nifty 50 is tanked 179 points and is trading at 10,685 while the Sensex is trading lower by 540 points at 35,435.
IOC 500408 500325 TCHQY 532755 511218 534816 SRRQY BJJQY GAILF EICHERMOT RLNIY 532749 APOLLOTYRE AYRQY 530965 517334 MRZUY 532500 TECHM 500182 BAJFINANCE TATASTEEL TATLY MARUTI 524370 GAILY SICAL TCS HINDCOPPER BODALCHEM BHRYY 533150 GODREJIND RELIANCE 533273 SRTRANSFIN BHRQY TTNQY 532259 505200 MOZTY 500470 532540 ALLCARGO RIGD 520086 INFRATEL HEROMOTOCO BHARTIARTL 503100 500034 INDIGO ECQRY APARINDS HINDALCO PHOENIXLTD 500877 513599 539448 532454 HNDNF OBZIY GODREJPROP TTST OBEROIRLTY MOTHERSUMI TATAELXSI HRTQY 500164 500440

14
KKR, Blackstone may acquire stake in Shriram Group for $3 billion: Report

2018-09-30 moneycontrol
KKR & Co and Blackstone Group have expressed interest in acquiring stake in Ajay Piramal’s finance conglomerate Shriram Group, sources told Bloomberg. The investment could be worth about $3 billion, they added.
511218 532498 BGX SHRIRAMCIT SRRQY BGLF BX SRTRANSFIN BGB

14
KKR, Blackstone Group weigh $3 billion Shriram deal

2018-09-28 livemint
Mumbai: KKR & Co. and Blackstone Group LP are among suitors that have expressed interest in acquiring a stake in Shriram Group, the Indian finance conglomerate backed by billionaire Ajay Piramal, people with knowledge of the matter said.
511218 532498 BGX SHRIRAMCIT SRRQY PRMQY BGLF BX 500302 SRTRANSFIN BGB PEL

1
How NBFCs found themselves in the middle of a storm

2018-09-27 livemint
It started when Infrastructure Leasing & Financial Services (IL&FS) defaulted on its payment obligations, followed by downgrades by credit agencies in the past two months. On 17 September, rating agency Icra downgraded IL&FS’s credit rating to default, after it failed to meet repayment obligations of ₹12,000 crore in short-term and long-term borrowings. It earlier defaulted on a ₹1,000 crore loan from the Small Industries Development Bank of India on 13 September.
511218 DHFL ICICIBANK HDB 511072 532174 IBN 500180 SRRQY HDFCBANK SRTRANSFIN

 
Was the NBFC meltdown waiting to happen?

2018-09-25 thehindubusinessline
Stocks of non-banking finance companies (NBFCs) have been in a free fall, rattling investors over the past few days. What began as a singular event, with one of the big names – IL&FS failing to repay its commercial paper dues – has blown into a possible liquidity crisis for the entire NBFC universe. Is the sharp fall in NBFC stocks justified?
GRUH 511072 IDKQY GRHFY SRTRANSFIN 511288 511218 535789 IBULHSGFIN DHFL LICHSGFIN SRRQY LHFLY 500253

 
Housing finance firms come crashing down

2018-09-22 freepressjournal.in
Mumbai : Shares of housing finance companies took a massive beating on Friday, with Dewan Housing Finance (DHFL) tumbling up to 42 per cent on massive selling over fears of a liquidity crisis, which had a cascading effect on the broader market as well.
YESBANK EDELWEISS 511072 IDKQY 532737 CANFINHOME 532648 YYBKY 532922 511196 SRTRANSFIN 511218 535789 IBULHSGFIN DHFL EMKAY BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 3772 500253 500034

 
DHFL stock cracks 42%; here#39;s what MD Kapil Wadhawan has to say about it

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged as much as 60 percent to hit fresh 52-week low of Rs 246.25 amid high volumes, but managed to trim a bit of losses on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
DHFL stock cracks 60% to below Rs 300; here#39;s what MD Kapil Wadhawan has to say about it

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged as much as 60 percent to hit fresh 52-week low of Rs 246.25 amid high volumes on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
DHFL stock halves to trade below Rs 400, other housing finance firms also follow suit

2018-09-21 moneycontrol
Dewan Housing Finance Corporation (DHFL) share price plunged 42.5 percent to hit fresh 52-week low of Rs 351.05 amid high volumes on Friday.
GRUH 511072 IDKQY GRHFY 535322 CANFINHOME 532978 511196 SRTRANSFIN 511288 REPCOHOME 511218 535789 IBULHSGFIN DHFL BAJAJFINSV BAJFINANCE LICHSGFIN SRRQY BJJQY LHFLY 500253 500034

 
Shriram Transport Finance recoups losses to rally 4% after management clarification on SVL case

2018-09-14 moneycontrol
Shriram Transport Finance Corporation share price fell nearly 4 percent in early trade but managed to recoup those losses to rally more than 4 percent intraday on Friday, after the management clarified on SVL case.
511218 532498 SHRIRAMCIT SRRQY SRTRANSFIN

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...